IAAG
AZN icon

Innovative Asset Advisors Group’s AstraZeneca AZN Stock Holding History

Innovative Asset Advisors Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102K Buy
540
+31
+6% +$5.83K 0.04% 227
2026
Q1 		$100K Buy
+509
New +$98.1K 0.06% 207

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Asset Management
Vanguard Asset Management London, Ec4n 8af $148B AUM
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $18.4B AUM 23.98% 1-Year Est. Return

Innovative Asset Advisors Group's AZN Position: Q2 2026 in Review

Innovative Asset Advisors Group increased its AstraZeneca (AZN) stake by 6.1% in Q2 2026, buying an estimated $5.83K and bringing the position to 540 shares worth $102K. The position accounts for 0.04% of the portfolio, ranked #227.

Innovative Asset Advisors Group first reported a position in AZN in Q1 2026 and has held it in 2 quarters since. 1,425 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Innovative Asset Advisors Group held 540 shares of AstraZeneca worth $102K as of Q2 2026.
  • Innovative Asset Advisors Group bought 31 AstraZeneca shares in Q2 2026, an estimated $5.83K.
  • AstraZeneca made up 0.04% of Innovative Asset Advisors Group's portfolio in Q2 2026, its #227 holding.
  • Innovative Asset Advisors Group first reported a position in AstraZeneca in Q1 2026 and has held it in 2 quarters since.
  • 1,425 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Innovative Asset Advisors Group's 13F filing for Q2 2026, filed 5 Aug 2026.